We are live on ! Find out more
WINT

Windtree Therapeutics
WINT

Delisted

WINT was delisted on the 20th of August, 2025.

Back to rankings

6 hedge funds and large institutions have $152K invested in Windtree Therapeutics in 2023 Q2 according to their latest regulatory filings, with 4 funds opening new positions, 1 increasing their positions, reducing their positions, and 0 closing their positions.

New
Increased
Maintained
Reduced
Closed

1,082% more capital invested

Capital invested by funds: $12.8K → $152K (+$139K)

200% more funds holding

Funds holding: 2 → 6 (+4)

0% more ownership

Funds ownership: 0% → 0% (+0%)

Holders
6
Holders Change
+4
Holders Change %
+200%
% of All Funds
0.09%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
4
Increased
1
Reduced
–
Closed
–
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
VF
Virtu Financial
New York
+$95.4K
2
Acadian Asset Management
Acadian Asset Management
Massachusetts
+$71.1K
3
Citadel Advisors
Citadel Advisors
Florida
+$48.7K
4
TSS
Two Sigma Securities
New York
+$38.6K
5
TRCT
Tower Research Capital (TRC)
New York
+$14.2K

Top Sellers

Rank Fund Capital Flow
1
GI
Gradient Investments
Minnesota
-$5

WINT Hedge Fund Activity: Q2 2023 in Review

6 of the 6,383 institutional investors tracked by Wall St. Rank reported a position in Windtree Therapeutics (WINT) for Q2 2023, worth a combined $152K — up 1,082% from $12.8K a quarter earlier.

Buyers outnumbered sellers: 4 funds opened new WINT positions and 0 closed out — a net gain of 4 holders — while 1 added to existing stakes and 0 trimmed.

The largest buyer was Virtu Financial, opening a new position worth an estimated $95.4K. The largest seller was Gradient Investments, cutting an estimated $5.

  • 6 institutional investors held Windtree Therapeutics (WINT) as of Q2 2023, up from 2 in Q1 2023.
  • Funds reported $152K of Windtree Therapeutics stock for Q2 2023, up 1,082% quarter-over-quarter.
  • 4 funds opened new Windtree Therapeutics positions in Q2 2023 and 0 closed out, a net change of +4 holders.
  • The largest Windtree Therapeutics buyer in Q2 2023 was Virtu Financial, an estimated $95.4K added.
  • The largest Windtree Therapeutics seller in Q2 2023 was Gradient Investments, an estimated $5 sold.

Based on aggregated 13F filings for Q2 2023.